Zobrazeno 1 - 10
of 141
pro vyhledávání: ''
Autor:
Ellinor Elinder, Jonas Bergh, Anne Andersson, Henrik Lindman, Jamila Adra, Yvonne Brandberg, Mats Hellström, Thomas Hatschek, Hemming Johansson, Aglaia Schiza, Hanna Fredholm, Ann Charlotte Dreifaldt, Edward Azavedo, Lena M. S. Carlsson, Ioannis Zerdes, Erika Isaksson-Friman, Ana Bosch, Johan Hartman, Susanne Agartz, Gyula Pekar, Tobias Lekberg, Zakaria Einbeigi, Per Grybäck, Claudia Maes, Theodoros Foukakis, Judith Bjöhle
Publikováno v:
JAMA Oncol
Importance Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. Objective To assess pathologic c
Autor:
Peter C. Lucas, Marc J. Gollub, Tracey E. Schefter, Bryan A. Faller, Richard K. Valicenti, Mark A O'Rourke, William Parker, Greg Yothers, Philip J. Stella, Samuel A. Jacobs, Osama E. Rahma, Radhika Kainthla, Thomas J. George, Y. Nancy You, Lisa A. Kachnic, Elin R. Sigurdson, Katherine M. Moxley, Norman Wolmark, Theodore S. Hong, William A. Hall, Namrata Vijayvergia, Linda H. Colangelo, Marcia M. Russell
Publikováno v:
JAMA Oncol
Importance Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations
Autor:
Werner Lichtenegger, Georg Heinrich, Inga Bekes, Julia Jückstock, Thomas W. P. Friedl, Robert E. Coleman, Matthias W. Beckmann, Volkmar Müller, Sara Y. Brucker, Ralf Lorenz, Sven Mahner, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Tanja Fehm, Lothar Häberle, Helmut Forstbauer, Jens Uwe Blohmer, Visnja Fink, Peter A. Fasching, Jens Huober, Brigitte Rack
Publikováno v:
JAMA Oncol
Importance Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. Objective To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patie
Publikováno v:
JAMA Oncol
Importance In immune checkpoint inhibitor (ICI) trials, long tails and crossovers in survival curves—which violate the proportional hazards (PH) assumption—are commonly observed, making cure or restricted mean survival time models preferable for
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Pei Loo Ow, Angel Garcia, Lesley Samuel, Rajarshi Roy, Adam McGeoch, D. Fyfe, W Saku, Simon Aird Grumett, Jonathan Nicoll, Jo Dent, Tom Samuel Waddell, Jo Webster, Christine Allmark, Tania Tillett, Colin Askill, Justin S. Waters, C. Handforth, Erica Beaumont, Vallipuram Vigneswaran, Sharon Ruddock, Nick Wadd, Syed Zubair, Kinnari Patel, Vanessa Potter, Daniel Propper, Olwyn Williams, Marc Jones, Kamalnayan Guptal, Peter Hall, Gareth Griffiths, Joseph Mano, Juan W. Valle, Sheela Rao, David A Cairns, Go Trial Investigators, Eszter Katona, Nick Maisey, Chris Twelves, Daniel Swinson, Nicholas Reed, Heike I. Grabsch, Joanne Askey, Jonathan Wadsley, Tom Roques, Sue Cheeseman, Stephen Falk, Louise Medley, Arshad Jamil, Emma Cattell, Victori Kunene, Matthew R. Sydes, Charles Candish, Claire Hobbs, Rebecca Herbertson, Jo Parkinson, Nicholas S. Reed, Louise Brook, Zuzana Stokes, Mohammed Khan, Ann Crossley, Elin Jones, George Bozas, Sebastian Cummins, Anirban Chatterjee, Michael Bennet, Helen Marshall, Pavel Bezecny, David Sherriff, Matthew T. Seymour, Lauren Gorf, Galina Velikova, Jean Gall, Kamposioras Konstantinos-Velios, Sally Clive, Eleanor James, Fiona Collinson, Dunca Wilkins, Simon Lord, Julia Brown, Serena Hilman, A. Robinson, Richard Ellis, Alaaeldin Shablak, Russell D Petty, Sherif Raouf, Helen Howard
Publikováno v:
Hall, P S, Swinson, D, A. Cairns, D, S. Waters, J, Petty, R, Allmark, C, Ruddock, S, Falk, S, Wadsley, J, Roy, R, Tillett, T, Nicoll, J, Cummins, S, Mano, J, Grumett, S, Stokes, Z, Konstantinos-Velios, K, Chatterjee, A, Garcia, A, Waddell, T, Guptal, K, Maisey, N, Khan, M, Dent, J, Lord, S, Crossley, A, Katona, E, Marshall, H, I. Grabsch, H, Velikova, G, Loo Ow, P, Handforth, C, Howard, H & T. Seymour, M 2021, ' Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerThe GO2 Phase 3 Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2021.0848
JAMA Oncology, 7(6), 869-877. American Medical Association
JAMA Oncology, 7(6), 869-877. American Medical Association
Importance: Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective: The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frai
Autor:
PharmD, Susamma M Wilson, Eduardo Bruera, Aline Rozman de Moraes, Zhanni Lu, Sriram Yennurajalingam, John M Najera, David Hui, Joseph Arthur, Tonya Edwards, Kristy Nguyen, Shirley Darlene Ethridge, Michal J Kubiak, Jimin Wu, Suresh K. Reddy, Yu Qian, Elif Erdogan, Saima Rashid, Manju P Joy, Leela Kuriakose, Jimi S Malik
Publikováno v:
JAMA Oncol
IMPORTANCE: One of the main aims of research on nonmedical opioid use (NMOU) is to reduce the frequency of NMOU behaviors through interventions such as universal screening, reduced opioid exposure, and more intense follow-up of patients with elevated
Autor:
N. Lynn Henry, Robert A. Bagramian, Mark M. Schubert, Amy K. Darke, Shaker R. Dakhil, Danika L. Lew, Catherine Van Poznak, James L. Wade, Dawn L. Hershman, Justin D. Floyd, Carol M. Moinpour, Michael J. Fisch, Joseph M. Unger, Lisa Hansen, Julie R. Gralow
Publikováno v:
JAMA Oncol
Importance Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. Objective To define the cumulative incidence of ONJ at 3 years in p
Publikováno v:
JAMA Oncol
Importance For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and s
Autor:
Kunle Odunsi, Peter J. Frederick, Emese Zsiros, Chong Wang, Kristopher Attwood, Shashikant Lele, Eduardo Cortes Gomez, Shanmuga Reddy Chilakapati, Sarah Lynam, Song Liu, S.N. Akers
Publikováno v:
JAMA Oncol
Importance Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies. Objective To assess the efficacy and safety of a com